Behandlung von tumoren durch immunologisches transplantat-engineering mittels therapeutischer apherese

Translated title of the contribution: Therapeutic apheresis immunologic graft engineering for the treatment of cancer

Research output: Contribution to journalArticle

Abstract

The role of therapeutic apheresis in the treatment of cancer has been mainly palliative by relieving symptoms produced by the underlying malignancy. Reports linking therapeutic apheresis with superior clinical outcomes in cancer patients were lacking until the discovery of graft-versus-tumor effect produced by the infusion of allo-reactive donor lymphocyte obtained during stem cell collection in allogeneic stem cell transplantation. Furthermore, the better clinical outcomes observed after relapse from allogeneic stem cell transplantation by infusing the patient with donor lymphocyte infusion suggested that therapeutic apheresis can be viewed as an adoptive immunotherapeutic strategy. However, the infused allo-reactive donor lymphocytes producing the graft-versus-tumor effect are also associated with the high morbility and mortality complication of graft-versus-host disease. Recent reports have shown that we can develop an autologous-graft-versus-tumor effect without the complication of graft-versus-host disease by manipulating the apheresis machine during stem cell collection for autologous stem cell transplantation. In this review, we address the rationale to use the apheresis machine to engineer immunocompetent autograft to improve survival in cancer patients.

Original languageGerman
Pages (from-to)379-382
Number of pages4
JournalTransplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft
Volume22
Issue number4
StatePublished - 2010

Fingerprint

Blood Component Removal
Transplants
Stem Cell Transplantation
Neoplasms
Tissue Donors
Graft vs Host Disease
Lymphocytes
Therapeutics
Stem Cells
Autografts
Recurrence
Survival
Mortality

Keywords

  • Autologous graft-versus-tumor effect
  • Cancer
  • Immunologic graft engineering
  • Survival
  • Therapeutic apheresis

ASJC Scopus subject areas

  • Transplantation

Cite this

@article{e2aac0e07784496ba1ccb228f20300c0,
title = "Behandlung von tumoren durch immunologisches transplantat-engineering mittels therapeutischer apherese",
abstract = "The role of therapeutic apheresis in the treatment of cancer has been mainly palliative by relieving symptoms produced by the underlying malignancy. Reports linking therapeutic apheresis with superior clinical outcomes in cancer patients were lacking until the discovery of graft-versus-tumor effect produced by the infusion of allo-reactive donor lymphocyte obtained during stem cell collection in allogeneic stem cell transplantation. Furthermore, the better clinical outcomes observed after relapse from allogeneic stem cell transplantation by infusing the patient with donor lymphocyte infusion suggested that therapeutic apheresis can be viewed as an adoptive immunotherapeutic strategy. However, the infused allo-reactive donor lymphocytes producing the graft-versus-tumor effect are also associated with the high morbility and mortality complication of graft-versus-host disease. Recent reports have shown that we can develop an autologous-graft-versus-tumor effect without the complication of graft-versus-host disease by manipulating the apheresis machine during stem cell collection for autologous stem cell transplantation. In this review, we address the rationale to use the apheresis machine to engineer immunocompetent autograft to improve survival in cancer patients.",
keywords = "Autologous graft-versus-tumor effect, Cancer, Immunologic graft engineering, Survival, Therapeutic apheresis",
author = "Porrata, {L. F.} and Markovic, {Svetomir Nenad}",
year = "2010",
language = "German",
volume = "22",
pages = "379--382",
journal = "Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft",
issn = "0946-9648",
publisher = "Pabst Science Publishers",
number = "4",

}

TY - JOUR

T1 - Behandlung von tumoren durch immunologisches transplantat-engineering mittels therapeutischer apherese

AU - Porrata, L. F.

AU - Markovic, Svetomir Nenad

PY - 2010

Y1 - 2010

N2 - The role of therapeutic apheresis in the treatment of cancer has been mainly palliative by relieving symptoms produced by the underlying malignancy. Reports linking therapeutic apheresis with superior clinical outcomes in cancer patients were lacking until the discovery of graft-versus-tumor effect produced by the infusion of allo-reactive donor lymphocyte obtained during stem cell collection in allogeneic stem cell transplantation. Furthermore, the better clinical outcomes observed after relapse from allogeneic stem cell transplantation by infusing the patient with donor lymphocyte infusion suggested that therapeutic apheresis can be viewed as an adoptive immunotherapeutic strategy. However, the infused allo-reactive donor lymphocytes producing the graft-versus-tumor effect are also associated with the high morbility and mortality complication of graft-versus-host disease. Recent reports have shown that we can develop an autologous-graft-versus-tumor effect without the complication of graft-versus-host disease by manipulating the apheresis machine during stem cell collection for autologous stem cell transplantation. In this review, we address the rationale to use the apheresis machine to engineer immunocompetent autograft to improve survival in cancer patients.

AB - The role of therapeutic apheresis in the treatment of cancer has been mainly palliative by relieving symptoms produced by the underlying malignancy. Reports linking therapeutic apheresis with superior clinical outcomes in cancer patients were lacking until the discovery of graft-versus-tumor effect produced by the infusion of allo-reactive donor lymphocyte obtained during stem cell collection in allogeneic stem cell transplantation. Furthermore, the better clinical outcomes observed after relapse from allogeneic stem cell transplantation by infusing the patient with donor lymphocyte infusion suggested that therapeutic apheresis can be viewed as an adoptive immunotherapeutic strategy. However, the infused allo-reactive donor lymphocytes producing the graft-versus-tumor effect are also associated with the high morbility and mortality complication of graft-versus-host disease. Recent reports have shown that we can develop an autologous-graft-versus-tumor effect without the complication of graft-versus-host disease by manipulating the apheresis machine during stem cell collection for autologous stem cell transplantation. In this review, we address the rationale to use the apheresis machine to engineer immunocompetent autograft to improve survival in cancer patients.

KW - Autologous graft-versus-tumor effect

KW - Cancer

KW - Immunologic graft engineering

KW - Survival

KW - Therapeutic apheresis

UR - http://www.scopus.com/inward/record.url?scp=78650196001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650196001&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:78650196001

VL - 22

SP - 379

EP - 382

JO - Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft

JF - Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft

SN - 0946-9648

IS - 4

ER -